Abstract Objective It is unclear whether the reduction of coronary restenosis by statins is due to a decrease in low-
Introduction

Atherosclerosis is the underlying disorder in most patients with coronary artery disease (CAD). The value of lowering low-density lipoprotein (LDL) cholesterol levels in preventing major cardiovascular events (1) and stroke has been well documented. Recent studies have raised the issue of the value of reducing LDL cholesterol levels to below 80 mg/dl in patients with CAD (2). In addition, Nissen et al also reported that the reduced rate of progression of atherosclerosis associated with intensive statin treatment (LDL cholesterol level was 78.9±30.2 mg/dl), compared with moderate statin treatment (110.4±25.8 mg/dl), is significantly related to a greater reduction in the levels of atherogenic lipoproteins and C-reactive protein (CRP) (3). Although statin therapy was associated with reduced restenosis after successful coronary stent implantation (4) and coronary artery bypass sur-gery (5), it is still unclear whether statins help to prevent coronary restenosis. In addition, stent implantation also provides a useful model for assessing the potential interrelation among serum evidence of inflammation, statin therapy and the progression of atherosclerotic disease, which is primarily determined by neointima formation. In addition cell adhesion molecules and chemokines have been implicated in the adhesion of leukocytes to endothelial cells and play a role in coronary atherosclerosis associated with inflammation
. Although these molecules regulate the different steps in leukocyte migration from the blood stream into the vessel wall and statin blocks these steps as pleiotropic effects (8) (Table 1) , while age and body mass index in the comparative group were significantly higher and lower than those in the statin group, respectively.
Methods
Subjects and design
Blood sampling
Blood sampling was performed before statin treatment, and after 1 day, 1 week and 6 months. Lipid profile, creactive protein (CRP), adhesion molecules, chemokines, plasma soluble(s)-intracellular adhesion molecule-I (sICAM-I), monocyte chemotactic protein-1 (MCP-1) and regulated upon activation, normal T cell-expressed and secreted (RANTES). When CRP was less than 0.3 mg/dl, highsensitivity assay for CRP was also performed. Expression of the following adhesion molecules, CC chemokine receptor (CCR) and CXC chemokine receptor (CXCR) on neutrophils, monocytes and lymphocytes was measured using flow cytometric analysis (Beckman Coulter, Fullerton, CA). Blood samples were anticoagulated with ethylene diamine tetra-acetic acid. Staining was performed in whole blood with fluorescein-isothiocyanate (FITC)-conjugated anti-CD11a, anti-CD18, anti-ICAM-1, anti-Lselectin, anti-very late antigen (VLA)-4α, anti-CCR2, anti-CCR5, anti-CXCR2, and anti-CXCR3 monoclonal antibodies (MAbs). Whole blood (100 μl) was incubated with saturating concentrations of FITC-conjugated
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Results
Patient characteristics
There were no differences in the incidences of hypertension and diabetes mellitus, medication (calcium channel blocker, β-blocker, nitroglycerin, diuretics, nicorandil and angiotensin receptor blocker), or type of stent, length, diameter and maximal inflation pressure between the groups
Angiographic and stent implantation procedure characteristics
As shown in Table 2 , there were no differences in the angiographic and stent implantation procedure characteristics between the groups.
Plasma levels of lipid profile, WBC, hCRP, s-ICAM-I, MCP-1 and RANTES
The levels of TC and LDL-C in the statin group were significantly higher than those in the comparative group (Table 3). In addition, the statin group showed a significant reduction of TC and LDL-C at 6 months. Although the ex-
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and s-ICAM-1 in both groups were similar at pre and 6 months, CRP in the statin group was significantly lower than that in the comparative group at 6 months. Table 5 . The % restenosis rate and % target lesion revascularization rate in the statin group were lower than those in the comparative group, but these differences were not significant. The MLD at 6 months in the statin group was significantly higher than that in the comparative group. The % DS in the comparative group, but not in the statin group, was significantly increased after 6 months. In addition, the late loss in the statin group was significantly lower.
Expression levels of adhesion molecules and chemokines in WBC
Although almost all of the expression levels of adhesion molecules and chemokines in leukocytes at 6 months decreased in both groups, there were no differences in the levels of adhesion molecules and chemokines between the groups at pre and 6 months (Table 4).
QCA results
QCA results are shown in
Changes in parameters
∆%DS was positively correlated with ∆LDL cholesterol and age in all of the patients (Fig. 1A and B) . In addition, patients with AMI who had an LDL cholesterol level of less than 80 mg/dl had a significantly lower ∆%DS (Fig. 1C) (Fig. 1D) . ∆% DS was significantly related to ∆LDL cholesterol, suggesting that the lowering of LDL cholesterol is the best contributor to decreased %DS.
Discussion
Although a drug-eluting stent is clinically available and useful for preventing restenosis (13) (Fig. 1C) , which is consistent with previous reports (2, 3) .
The increased expression of cellular adhesion molecules and chemokines on leukocytes and endothelial cells is an essential step in atherosclerosis (6) . The adhesion molecules (14, 15) and chemokines (16) (17) and chemokines, MCP-1 (18, 19) A. Co r r e l a t i o n b e t we e n c h a n g e s i n % d i a me t e r s t e n o s i s ( DS ) b e t we e n b e f o r e a n d a f t e r s t a t i n t r e a t me n t a t 6 mo n t h s ( Δ %DS ) a n d Δ l o w-d e n s i t y l i p o p r o t e i n ( L DL ) c h o l e s t e r o l i n a l l p a t i e n t s . n = 5 0 , r = 0 . 3 5 0 , p = 0 . 0 1 3 . y = 0 . 1 9 8 X + 2 0 . 4 0 4 . Cl o s e d a n d o p e n c i r c l e s i n d i c a t e s t a t i n a n d c o mp a r a t i v e g r o u p s , r e s p e c t i v e l y . B . Co r r e l a t i o n b e t we e n c h a n g e s i n Δ %DS a n d a g e i n a l l p a t i e n t s . n = 5 0 , r = 0 . 3 3 8 , p = 0 . 0 1 6 . y = 0 . 5 3 5 X -2 0 . 0 4 1 . Cl o s e d a n d o p e n c i r c l e s i n d i c a t e s t a t i n a n d c o mp a r a t i v e g r o u p s , r e s p e c t i v e l y . C. Re l a t i o n b e t we e n L DL c h o l e s t e r o l q u a r t i l e a t 6 mo n t h s a n d Δ %DS . Va l u e s a r e s h o wn a s me a n ± s t a n d a r d e r r o r . 
have been shown to be significantly related to cardiovascular events among patients with coronary artery disease (CAD). Statin treatment leads to a decrease in adhesion molecules, such as CD11a/CD18
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